Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.83 |
| ▸ | RAB9A | P51151 | 2/20 | 0.83 |
| ▸ | HSD17B3 | P37058 | 8/20 | 0.66 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27774936 | 0.96 | NPC1 (0.76) | NPC1RAB9AHSD17B3PDE4BHDAC3 | |
| SCHEMBL1115033 | 0.94 | NPC1 (0.73) | NPC1RAB9AHSD17B3PDE4BHDAC3 | |
| SCHEMBL8733595 | 0.91 | NPC1 (1.00) | NPC1RAB9AHSD17B3L3MBTL1GAA | |
| SCHEMBL2632218 | 0.87 | RAB9A (0.68) | NPC1RAB9AHSD17B3L3MBTL1GAA | |
| SCHEMBL124008 | 0.87 | NPC1 (0.91) | NPC1RAB9AHSD17B3HDAC3HDAC4 | |
| SCHEMBL8614024 | 0.85 | NPC1 (0.86) | NPC1RAB9AHSD17B3HDAC3HDAC4 | |
| SCHEMBL8519713 | 0.85 | NPC1 (0.86) | NPC1RAB9AHSD17B3HDAC3HDAC4 | |
| SCHEMBL7163686 | 0.85 | NPC1 (0.86) | NPC1RAB9AHSD17B3HDAC3HDAC4 | |
| SCHEMBL10341614 | 0.85 | NPC1 (0.86) | NPC1RAB9AHSD17B3HDAC3HDAC4 | |
| SCHEMBL10341631 | 0.85 | NPC1 (0.86) | NPC1RAB9AHSD17B3HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069702-A1 | Drug Compounds Comprising Albumin-Binding Moieties | ASCENDIS PHARMA AS (DK) | 2026-03-12 | — | — | US | disclosed |
| US-20210220442-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2021-07-22 | — | — | US | disclosed |
| EP-3050576-B1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA ENDOCRINOLOGY DIV A/S (DK) | 2021-03-31 | — | — | EP | disclosed |
| US-10960053-B2 | PEGylated recombinant human growth hormone compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2021-03-30 | — | — | US | disclosed |
| US-20190192634-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2019-06-27 | — | — | US | disclosed |
| EP-3050576-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | Ascendis Pharma Growth Disorders Division A/S (DK) | 2016-08-03 | — | — | EP | disclosed |
| US-20160206702-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2016-07-21 | — | — | US | disclosed |
| US-20160206702-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2016-07-21 | — | — | US | disclosed |
| EP-2279007-B1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA GROWTH DISORDERS DIVISION AS (DK) | 2016-05-18 | — | — | EP | disclosed |
| US-9272048-B2 | PEGylated recombinant human growth hormone compounds | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2016-03-01 | — | — | US | disclosed |
| US-9272048-B2 | PEGylated recombinant human growth hormone compounds | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2016-03-01 | — | — | US | disclosed |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | ASCENDIS PHARMA AS (DK) | 2012-03-08 | — | — | US | disclosed |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | ASCENDIS PHARMA AS (DK) | 2012-03-08 | — | — | US | disclosed |
| US-20110112021-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA AS (DK) | 2011-05-12 | — | — | US | disclosed |
| US-20110112021-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA AS (DK) | 2011-05-12 | — | — | US | disclosed |
| EP-1401433-B1 | AZOLE ACID DERIVATIVES, ALONE OR IN COMBINATION, FOR TREATING DIABETES AND DYSLIPIDEMIAS; AND FOR TREATING MALIGNANT DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2010100220-A1 | INTERFERON ALPHA CARRIER PRODRUGS | ASCENDIS PHARMA AS (DK) | 2010-09-10 | — | — | WO | disclosed |
| WO-2009133137-A2 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA AS (DK) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10960053-B2 | PEGylated recombinant human growth hormone compounds | GHRHR, GHITM, GHSR | NPC1 3435/4885RAB9A 3195/4885HSD17B3 611/4885 |
| US-20190192634-A1 | PEGylated Recombinant Human Growth Hormone Compounds | GHRHR, GHITM, GHSR | NPC1 3435/4885RAB9A 3195/4885HSD17B3 611/4885 |
| US-20110112021-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | GHRHR, GHITM, GHSR | NPC1 3435/4885RAB9A 3195/4885HSD17B3 611/4885 |
| US-20160206702-A1 | PEGylated Recombinant Human Growth Hormone Compounds | GHRHR, GHITM, GHSR | NPC1 3435/4885RAB9A 3195/4885HSD17B3 611/4885 |
| US-20210220442-A1 | PEGylated Recombinant Human Growth Hormone Compounds | GHRHR, GHITM, GHSR | NPC1 3435/4885RAB9A 3195/4885HSD17B3 611/4885 |
| US-20260069702-A1 | Drug Compounds Comprising Albumin-Binding Moieties | ALB, GLP1R, SELPLG | NPC1 2474/4885RAB9A 3730/4885HSD17B3 2401/4885 |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | IFNG, IFNAR1, IRF3 | NPC1 861/4885RAB9A 2931/4885HSD17B3 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.